In this article, we will discuss Palifermin and Carcinogenicity. So, let’s get started.
Palifermin and Carcinogenicity
No treatment-related increase in the incidence of neoplastic lesions occurred in transgenic rasH2 mice treated with 9 weekly intravenous doses of palifermin, at 167-fold higher than the recommended human dose (on a mcg/kg basis).